Literature DB >> 10897148

Effect of ganaxolone on flurothyl seizures in developing rats.

S Liptáková1, L Velísek, J Velísková, S L Moshé.   

Abstract

PURPOSE: To determine the effects of a newly synthesized epalon, ganaxolone (GNX), on primarily generalized seizures in rats of various ages during development. Epalons are classified as neuroactive steroids that interact at unique site of the GABAA receptor-Cl- channel complex in the central nervous system.
METHODS: Sprague-Dawley male rats were used at 9, 15, 30, and 60 postnatal days (PN). GNX dissolved in 2-hydroxypropylbeta-cyclodextrine was administered intraperitoneally in different doses at various time points before flurothyl testing. The incidence and threshold of clonic and tonic-clonic flurothyl seizures were evaluated. Behavioral changes were also assessed.
RESULTS: In all age groups, the effects of GNX were dose dependent and more prominent 10 min after its administration. In PN 60 and PN 30 rats, GNX had dose-dependent anticonvulsant effects; tonic-clonic seizures were more sensitive to GNX treatment than clonic seizures. In PN 15 and PN 9 rats, GNX demonstrated dose-and time-dependent anticonvulsant effects against both types of flurothyl-induced seizures. GNX was more effective in PN 15 rats than in other age groups, but at doses that altered motor behavior.
CONCLUSIONS: GNX has anticonvulsant effects against flurothylinduced seizures in all age groups tested. Its effects are more prominent in the two younger age groups, especially in PN 15 rats, but are associated with motor side effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897148     DOI: 10.1111/j.1528-1157.2000.tb00244.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model.

Authors:  Doodipala S Reddy; Michael A Rogawski
Journal:  Epilepsy Res       Date:  2010-02-20       Impact factor: 3.045

Review 2.  Clinical Potential of Neurosteroids for CNS Disorders.

Authors:  Doodipala Samba Reddy; William A Estes
Journal:  Trends Pharmacol Sci       Date:  2016-05-05       Impact factor: 14.819

Review 3.  Ganaxolone.

Authors:  Virinder Nohria; Earl Giller
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 4.  Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Neurobiol Dis       Date:  2015-05-09       Impact factor: 5.996

Review 5.  The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Epilepsy Res       Date:  2009-04-29       Impact factor: 3.045

6.  3β-Methyl-Neurosteroid Analogs Are Preferential Positive Allosteric Modulators and Direct Activators of Extrasynaptic δ-Subunit γ-Aminobutyric Acid Type A Receptors in the Hippocampus Dentate Gyrus Subfield.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2018-03-30       Impact factor: 4.030

7.  Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Front Endocrinol (Lausanne)       Date:  2011-10-05       Impact factor: 5.555

Review 8.  Ganaxolone: A New Treatment for Neonatal Seizures.

Authors:  Tamara Yawno; Suzie L Miller; Laura Bennet; Flora Wong; Jonathan J Hirst; Michael Fahey; David W Walker
Journal:  Front Cell Neurosci       Date:  2017-08-22       Impact factor: 5.505

9.  Ganaxolone enhances microglial clearance activity and promotes remyelination in focal demyelination in the corpus callosum of ovariectomized rats.

Authors:  Abdeslam Mouihate; Samah Kalakh
Journal:  CNS Neurosci Ther       Date:  2019-07-22       Impact factor: 5.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.